Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 18.

Melzer, J; Rostock, M; Brignoli, R; Keck, M E; Saller, R (2012). Preliminary data of a HAMD-17 validated symptom scale derived from the ICD-10 to diagnose depression in outpatients. Forschende Komplementärmedizin, 19(4):191-196.

Keck, M E; Ropohl, A; Rufer, M; Hemmeter, U M; Bondolfi, G; Preisig, M; Rennhard, S; Hatzinger, M; Holsboer-Trachsler, E; Hättenschwiler, J; Seifritz, E (2011). Die Behandlung der Angsterkrankungen. Teil 1: Panikstörung, Agoraphobie, generalisierte Angststörung, soziale Phobie, spezifische Phobien. Swiss Medical Forum, 11(34):558-566.

Melzer, J; Keck, M E (2011). Phytotherapie in der Psychiatrie - gestern, heute, morgen. Ars Medici, 101(1):16-20.

Melzer, J; Brignoli, R; Keck, M E; Saller, R (2010). A Hypericum extract in the treatment of depressive symptoms in outpatients: an open study. Forschende Komplementärmedizin, 17(1):7-14.

Erhardt, A; Müller, M B; Rödel, A; Welt, T; Ohl, F; Holsboer, F; Keck, M E (2009). Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OlaHsd mice--influence of treatment with the CRHR1-antagonist R121919/NBI 30775. Journal of Psychopharmacology, 23(1):31-39.

Toschi, N; Welt, T; Guerrisi, M; Keck, M E (2009). Transcranial magnetic stimulation in heterogeneous brain tissue: clinical impact on focality, reproducibility and true sham stimulation. Journal of Psychiatric Research, 43(3):255-264.

Toschi, N; Welt, T; Guerrisi, M; Keck, M E (2008). A reconstruction of the conductive phenomena elicited by transcranial magnetic stimulation in heterogeneous brain tissue. Physica Medica, 24(2):80-86.

Thoeringer, C K; Binder, E B; Salyakina, D; Erhardt, A; Ising, M; Unschuld, P G; Kern, N; Lucae, S; Brueckl, T M; Mueller, M B; Fuchs, B; Puetz, B; Lieb, R; Uhr, M; Holsboer, F; Mueller-Myhsok, B; Keck, M E (2007). Association of a Met88Val diazepam binding inhibitor (DBI) gene polymorphism and anxiety disorders with panic attacks. Journal of Psychiatric Research, 41(7):579-584.

Unschuld, P G; Ising, M; Erhardt, A; Lucae, S; Kloiber, S; Kohli, M; Salyakina, D; Welt, T; Kern, N; Lieb, R; Uhr, M; Binder, E B; Müller-Myhsok, B; Holsboer, F; Keck, M E (2007). Polymorphisms in the serotonin receptor gene HTR2A are associated with quantitative traits in panic disorder. American Journal of Medical Genetics. Part B, 144B(4):424-429.

Nguyen, N K; Keck, M E; Hetzenauer, A; Thoeringer, C K; Wurst, W; Deussing, J M; Holsboer, F; Müller, M B; Singewald, N (2006). Conditional CRF receptor 1 knockout mice show altered neuronal activation pattern to mild anxiogenic challenge. Psychopharmacology, 188(3):374-385.

Welt, T; Engelmann, M; Renner, U; Erhardt, A; Müller, M B; Landgraf, R; Holsboer, F; Keck, M E (2006). Temazepam triggers the release of vasopressin into the rat hypothalamic paraventricular nucleus: novel insight into benzodiazepine action on hypothalamic-pituitary-adrenocortical system activity during stress. Neuropsychopharmacology, 31(12):2573-2579.

Keck, M E; Ströhle, A (2005). Challenge studies in anxiety disorders. In: Holsboer, F; Ströhle, A. Anxiety and Anxiolytic Drugs. Berlin [etc.]: Springer, 449-468.

Keck, M E; Sartori, S B; Welt, T; Müller, M B; Ohl, F; Holsboer, F; Landgraf, R; Singewald, N (2005). Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment. Journal of Neurochemistry, 92(5):1170-1179.

Tichomirowa, M A; Keck, M E; Schneider, H J; Paez-Pereda, M; Renner, U; Holsboer, F; Stalla, G K (2005). Endocrine disturbances in depression. Journal of Endocrinological Investigation, 28(1):89-99.

Keck, M E; Ohl, F; Holsboer, F; Müller, M B (2005). Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neuroscience and Biobehavioral Reviews, 29(4-5):867-889.

Keck, M E; Müller, M B (2005). Mutagenesis and knockout models: hypothalamic-pituitary-adrenocortical system. In: Holsboer, F; Ströhle, A. Anxiety and Anxiolytic Drugs. Berlin [etc.]: Springer, 113-141.

Keck, M E; Welt, T; Müller, M B; Uhr, M; Ohl, F; Wigger, A; Toschi, N; Holsboer, F; Landgraf, R (2003). Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology, 28(2):235-243.

Keck, M E; Welt, T; Müller, M B; Landgraf, R; Holsboer, F (2003). The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry, 36(1):27-31.

This list was generated on Wed Nov 21 09:02:32 2018 CET.